Nautilus Biotechnology (NAUT) Shares Outstanding (Weighted Average) (2020 - 2026)

Nautilus Biotechnology has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $126.6 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $126.6 million, changed 0.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $126.6 million (changed 0.39% YoY), and the FY2025 annual result was $126.3 million, up 0.66% from the prior year.
• Shares Outstanding (Weighted Average) came in at $126.6 million for Q1 2026 at Nautilus Biotechnology, roughly flat from $126.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $126.6 million in Q1 2026 to a low of $124.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $125.1 million (2024), against an average of $125.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 277.03% in 2022 and advanced 0.12% in 2023, its largest moves.
• Nautilus Biotechnology's Shares Outstanding (Weighted Average) stood at $124.6 million in 2022, then climbed by 0.26% to $124.9 million in 2023, then grew by 0.41% to $125.4 million in 2024, then climbed by 0.66% to $126.3 million in 2025, then climbed by 0.3% to $126.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $126.6 million (Q1 2026), $126.3 million (Q4 2025), and $126.3 million (Q3 2025), per Business Quant data.